title: Review: rosiglitazone increases risk for MI but does not differ from other drugs for CV death in type 2 diabetes.
authors.affiliation: Stanford University School of Medicine, Stanford, California, USA.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Hlatky
authors.forename: Dena M
authors.initials: DM
authors.lastname: Bravata